<DOC>
	<DOCNO>NCT01569295</DOCNO>
	<brief_summary>This Phase 3 , randomize , double-blind , placebo-controlled study evaluate effect idelalisib onset , magnitude , duration tumor control . Eligible patient randomize 1:1 ratio 1 2 treatment arm receive either idelalisib placebo . All subject administer bendamustine rituximab .</brief_summary>
	<brief_title>A Randomized , Double-Blind Placebo-Controlled Study Idelalisib Combination With Bendamustine Rituximab Previously Treated Chronic Lymphocytic Leukemia ( CLL )</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Idelalisib</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<criteria>Previously treat recurrent CLL Measurable lymphadenopathy Requires therapy CLL Has experience CLL progression &lt; 36 month since completion last prior therapy Recent history major nonCLL malignancy Evidence ongoing infection CLL refractory bendamustine Concurrent participation another therapeutic clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Zydelig</keyword>
	<keyword>CLL</keyword>
	<keyword>CAL 101</keyword>
	<keyword>CAL-101</keyword>
	<keyword>GS 1101</keyword>
	<keyword>GS-1101</keyword>
	<keyword>PI3K</keyword>
	<keyword>Rituxan</keyword>
	<keyword>Rituximab</keyword>
	<keyword>Bendamustine</keyword>
	<keyword>Leukemia</keyword>
	<keyword>idelalisib</keyword>
</DOC>